title: Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits.
abstract: The proenzyme single-chain urokinase plasminogen activator (scuPA) more effectively resolved intrapleural loculations in rabbits with tetracycline (TCN)-induced loculation than a range of clinical doses of two-chain uPA (Abbokinase) and demonstrated a trend toward greater efficacy than single-chain tPA (Activase) (Idell S et al., Exp Lung Res 33: 419, 2007.). scuPA more slowly generates durable intrapleural fibrinolytic activity than Abbokinase or Activase, but the interactions of these agents with inhibitors in pleural fluids (PFs) have been poorly understood. PFs from rabbits with TCN-induced pleural injury treated with intrapleural scuPA, its inactive Ser195Ala mutant, Abbokinase, Activase, or vehicle, were analyzed to define the mechanism by which scuPA induces durable fibrinolysis. uPA activity was elevated in PFs of animals treated with scuPA, correlated with the ability to clear pleural loculations, and resisted (70-80%) inhibition by PAI-1. Alpha-macroglobulin (alphaM) but not urokinase receptor complexes immunoprecipitated from PFs of scuPA-treated rabbits retained uPA activity that resists PAI-1 and activates plasminogen. Conversely, little plasminogen activating or enzymatic activity resistant to PAI-1 was detectable in PFs of rabbits treated with Abbokinase or Activase. Consistent with these findings, PAI-1 interacts with scuPA much slower than with Activase or Abbokinase in vitro. An equilibrium between active and inactive scuPA (k(on) = 4.3 h(-1)) limits the rate of its inactivation by PAI-1, favoring formation of complexes with alphaM. These observations define a newly recognized mechanism that promotes durable intrapleural fibrinolysis via formation of alphaM/uPA complexes. These complexes promote uPA-mediated plasminogen activation in scuPA-treated rabbits with TCN-induced pleural injury.
authors: Texas Lung Injury Institute of The University of Texas Health Science Center at Tyler, Tyler, Texas 75708, USA. andrey.komissarov@uthct.edu
authors: Andrey A
authors: AA
authors: Komissarov
authors: Andrew P
authors: AP
authors: Mazar
authors: Kathy
authors: K
authors: Koenig
authors: Anna K
authors: AK
authors: Kurdowska
authors: Steven
authors: S
authors: Idell
mesh_terms: D000818:Animals; D015153:Blotting, Western; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D047468:Immunoprecipitation; D017395:Plasminogen Activator Inhibitor 1 / Q000494:pharmacology*; D010994:Pleura / Q000187:drug effects* / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000633:toxicity; D011817:Rabbits; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins / Q000494:pharmacology; D013752:Tetracycline / Q000633:toxicity*; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism / Q000494:pharmacology*; D000511:alpha-Macroglobulins / Q000494:pharmacology*
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D011500:Protein Synthesis Inhibitors; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins; D000511:alpha-Macroglobulins; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D013752:Tetracycline